Navigation Links
A Drug With Efficacy Superior to That of Remicade at Inducing Closure and Healing of Fistulas Would Earn a 30 Percent Patient Share in the Crohn's Disease Drug Market
Date:6/11/2008

Ustekinumab Will Earn a 5.4 Percent Patient Share by 2012, According to a

New Report from Decision Resources

WALTHAM, Mass., June 11 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a therapy that induces closure and healing of fistulas in a greater percentage of patients than Centocor/Schering-Plough/Mitsubishi Tanabe's Remicade (infliximab) does, would earn a 30 percent patient share in the treatment of Crohn's disease, according to surveyed gastroenterologists.

The new report entitled Crohn's Disease: Physicians Seek Drugs That Treat Fistulizing Disease More Effectively than Infliximab finds that surveyed gastroenterologists indicated that they would prescribe Centocor/Janssen-Cilag's ustekinumab to 30 percent of their patients with Crohn's disease. As a result, ustekinumab is forecasted to earn a 5.4 percent patient share of the U.S. Crohn's disease market in 2012.

The report also finds that UCB's Cimzia will earn Decision Resources' proprietary clinical gold standard ("clinical gold standard") status for the treatment of Crohn's disease by 2011 as interviewed gastroenterologists indicate that Cimzia's efficacy and delivery profiles are superior to those of the current clinical gold standard, Abbott/Eisai's Humira. Although surveyed gastroenterologists indicated that Cimzia has advantages in efficacy and delivery, the therapy may be associated with more minor side effects when compared to Humira.

"Interviewed gastroenterologists report that Cimzia's pegylated formulation may prolong the drug's effect, resulting in a slightly more effective maintenance therapy with a superior maintenance dosing schedule in comparison to Humira," said Kathryn Benton, analyst at Decision Resources. "As a result, we forecast Cimzia to replace Humira as the clinical gold standard because of its incremental advantage in delivery
'/>"/>

SOURCE Decision Resources Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. USC researchers identify genetic markers that predict efficacy of novel cancer drug
2. Ohio State University Medical Center to Test Efficacy of Hyperbaric Oxygen Medicine on Stroke Victims
3. Pilot Study to Assess Safety and Efficacy of Medidur(TM) FA in AMD Patients Treated With Lucentis(R)
4. Shire investigational nonstimulant INTUNIV showed significant efficacy in reducing ADHD symptoms
5. Efficacy of FluMist(R) in Children Highlighted at Pediatric Academic Societies Meeting
6. Labopharm Appeals FDAs Decision on Once-Daily Tramadol to Next Supervisory Level After Additional Analysis Supports Efficacy
7. Gamma Secretase Modulators Show Promise in Alzheimers Disease Animal Model Efficacy Studies, According to Research Conducted by TorreyPines Therapeutics
8. Largest ever analysis of DES data demonstrates safety, efficacy in on-and-off-label use
9. GSK Data Suggests Efficacy of Advair(R) and Serevent(R) is Not Impacted by Genetic Profile
10. A Drug With Efficacy Superior to That of Memantine Would Earn up to a 50% Patient Share in the Moderate-to-Severe Alzheimers Disease Drug Market
11. What are simple ways to judge the efficacy of 5-fluorouracil in colonic neoplasm?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 17, 2014 Project Veritas is releasing ... videos of MIT economist and Obamacare architect Jonathan Gruber ... O’Keefe conducted the interview, which is being distributed on ... was intentional mislabeling in the Affordable Care Act in ... A two-hundred-and-fifty billion dollar per year tax grab. , ...
(Date:12/17/2014)... Alan Mozes HealthDay ... In the world of infectious diseases, one worrisome phenomenon is ... people. The process -- known as zoonosis -- is ... look for signs that an animal-borne disease might make inroads ... just such a development -- and the culprits in this ...
(Date:12/17/2014)... 2014 (HealthDay News) -- Poor students get more fruits and ... study finds. But, the opposite is true for students ... and vegetables at school may give a healthy boost to ... matter what the family income level, students all ate a ... found. The study was published recently in the journal ...
(Date:12/17/2014)... By Alan Mozes ... -- With the holiday party season fast approaching, a new ... and make DUI arrests have fewer drunk drivers on their ... driving laws more vigilantly are better able to deter inebriated ... "Hardly any new laws are being passed regarding drinking ...
(Date:12/17/2014)... Kathleen Doheny HealthDay Reporter ... loss is rampant in America, and work commitment is a ... No. 1 sleep killer," said Dr. Mathias Basner, an assistant ... of Pennsylvania Perelman School of Medicine. A time-use survey ... that work is the main activity exchanged for sleep. Short ...
Breaking Medicine News(10 mins):Health News:Project Veritas: James O’Keefe Interviews the Man Who Discovered Jonathan Gruber Videos 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 3Health News:Poor Students Eat Healthier Foods at School, Study Finds 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 3Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3
... , WEDNESDAY, Nov. 17 (HealthDay News) -- Diabetics may ... is just a cell phone screen away. Researchers ... phone monitoring system that automatically picks up patients, home ... via radio signals from monitoring equipment outfitted with Blue-tooth ...
... mysterious culprit that threatens headaches, stuffy noses, skin rash ... people worldwide drink wine. The discovery could help winemakers ... and whites with less potential to trigger allergy symptoms, ... Journal of Proteome Research . Giuseppe ...
... WEDNESDAY, Nov. 17 (HealthDay News) -- The U.S. Food and ... that their products are illegal. In warning letters to ... malt beverages is an "unsafe food additive," and the companies ... does not find support for the claim that the addition ...
... not been high on the list of targets for treating ... the development of neurodegenerative diseases than has been realized. ... the pericyte in a surprising new role as a key ... brain tissue from harmful substances. By manipulating pericyte levels, scientists ...
... News) -- Get ready, get set, quit! Thursday marks ... which urges all smokers to lay off the habit for at ... about smoking and a large decrease in smoking rates since the ... local and nationwide events meant to encourage smokers to quit for ...
... 17, 2010) HealthGrades, the nation,s leading independent ... patients a list of those hospitals with the ... receiving a donor organ. HealthGrades annual evaluation of ... clinical quality data, based on patient outcomes, for ...
Cached Medicine News:Health News:Cell Phone 'Telemonitoring' May Help Control Blood Pressure 2Health News:Cell Phone 'Telemonitoring' May Help Control Blood Pressure 3Health News:FDA Cracks Down on Caffeinated Alcohol Drinks 2Health News:FDA Cracks Down on Caffeinated Alcohol Drinks 3Health News:The pericyte becomes a player in Alzheimer's, other diseases 2Health News:The pericyte becomes a player in Alzheimer's, other diseases 3Health News:The pericyte becomes a player in Alzheimer's, other diseases 4Health News:Smokers Urged to Join Thursday's Great American Smokeout 2Health News:Nation's top hospital organ transplant centers identified by HealthGrades 2
(Date:12/15/2014)... Research and Markets ( http://www.researchandmarkets.com/research/32cmct/inferior_vena ) ... Cava (IVC) Filters - Global Trends, Estimates and Forecasts, ... http://photos.prnewswire.com/prnh/20130307/600769 Global Inferior Vena ... million by 2016. The North America ... value while Europe claims approximately ...
(Date:12/15/2014)... BRIDGEWATER, N.J. , Dec. 15, 2014 ... US (EURONEXT: SAN and NYSE: SNY) are collaborating with ... Cholesterol Counts , an awareness program that will ... and the risks associated with high LDL-C (bad cholesterol). ... .com to take a brief poll and answer ...
(Date:12/15/2014)... --  DaVita HealthCare Partners Inc.  (NYSE: ... most innovative health care communities, today announced that ... Research  (DCR) and  HealthCare Partners Clinical Research , will ... research and data analytics services, specifically in patients ... disease (ESRD), as well as primary care and ...
Breaking Medicine Technology:Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 2Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 4Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 2Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 3Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 4Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 5Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 6DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 2DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 3DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 4
... Incorporated (Nasdaq: VPHM ) today announced that ... of the European Medicines Agency (EMA) has adopted a ... Authorization (PUMA) for Buccolam® (midazolam, oromucosal solution), for treatment ... and adolescents, from 3 months to less than 18 ...
... serving Virginia patients reduced healthcare-acquired infection rates (HAIs) a ... of $1.2 million in additional costs to the health ... existing federal hand washing protocols, these hospitals improved patient ... patient length-of-stay and unnecessary readmissions. VHHA Services, ...
Cached Medicine Technology:ViroPharma Announces Positive CHMP Opinion for Buccolam® (Midazolam, Oromucosal Solution) in the European Union 2ViroPharma Announces Positive CHMP Opinion for Buccolam® (Midazolam, Oromucosal Solution) in the European Union 3ViroPharma Announces Positive CHMP Opinion for Buccolam® (Midazolam, Oromucosal Solution) in the European Union 4ViroPharma Announces Positive CHMP Opinion for Buccolam® (Midazolam, Oromucosal Solution) in the European Union 5Virginia Hospitals Reduce Infections 41% 2Virginia Hospitals Reduce Infections 41% 3
Compression Bra...
Post-Surgical compression garments...
... The Albumin Cobalt Binding (ACB®) Test is ... Modified Albumin (IMA®) by measuring the cobalt ... serum sample. First identified in the early ... comes in contact with ischemic tissue in ...
... Test is a clinical chemistry assay that ... the cobalt binding capacity of albumin in ... the early 1990s, IMA is produced when ... tissue in the heart. During ischemia, the ...
Medicine Products: